105 related articles for article (PubMed ID: 22511271)
21. Anticoagulant activities of curcumin and its derivative.
Kim DC; Ku SK; Bae JS
BMB Rep; 2012 Apr; 45(4):221-6. PubMed ID: 22531131
[TBL] [Abstract][Full Text] [Related]
22. Antithrombotic and anticoagulant profiles of TAK-442, a novel factor Xa inhibitor, in a rabbit model of venous thrombosis.
Kawamura M; Konishi N; Hiroe K; Shofuda K; Imaeda Y; Fujimoto T; Kubo K
J Cardiovasc Pharmacol; 2010 Aug; 56(2):156-61. PubMed ID: 20410831
[TBL] [Abstract][Full Text] [Related]
23. Effects of simvastatin on cigarette smoke extract induced tissue-type plasminogen activator and plasminogen activator inhibitor-1 expression in human umbilical vein endothelial cells.
Hu XY; Ma YH; Wang C; Yang YH
Chin Med J (Engl); 2009 Oct; 122(19):2380-5. PubMed ID: 20079143
[TBL] [Abstract][Full Text] [Related]
24. Less pronounced enhancement of thrombin-dependent inactivation of plasminogen activator inhibitor type 1 by low molecular weight heparin compared with unfractionated heparin.
Nakamura R; Umemura K; Hashimmoto H; Urano T
Thromb Haemost; 2006 Apr; 95(4):637-42. PubMed ID: 16601834
[TBL] [Abstract][Full Text] [Related]
25. Profibrinolytic activity of the direct thrombin inhibitor melagatran and unfractionated heparin in platelet-poor and platelet-rich clots.
Semeraro F; Piro D; Rossiello MR; Ammollo T; Colucci M
Thromb Haemost; 2007 Dec; 98(6):1208-14. PubMed ID: 18064315
[TBL] [Abstract][Full Text] [Related]
26. Vascular barrier protective effects of phlorotannins on HMGB1-mediated proinflammatory responses in vitro and in vivo.
Kim TH; Ku SK; Lee T; Bae JS
Food Chem Toxicol; 2012 Jun; 50(6):2188-95. PubMed ID: 22504532
[TBL] [Abstract][Full Text] [Related]
27. The contribution of anti-Xa and anti-IIa activities to the profibrinolytic activity of low-molecular-weight heparins.
Ammollo CT; Semeraro F; Semeraro N; Colucci M
Thromb Haemost; 2009 Apr; 101(4):782-5. PubMed ID: 19350129
[No Abstract] [Full Text] [Related]
28. The inhibitory effects of eckol and dieckol from Ecklonia stolonifera on the expression of matrix metalloproteinase-1 in human dermal fibroblasts.
Joe MJ; Kim SN; Choi HY; Shin WS; Park GM; Kang DW; Kim YK
Biol Pharm Bull; 2006 Aug; 29(8):1735-9. PubMed ID: 16880634
[TBL] [Abstract][Full Text] [Related]
29. Selection of S18326 as a new potent and selective boronic acid direct thrombin inhibitor.
Rupin A; Mennecier P; Lila C; de Nanteuil G; Verbeuren TJ
Thromb Haemost; 1997 Oct; 78(4):1221-7. PubMed ID: 9364988
[TBL] [Abstract][Full Text] [Related]
30. Activated human protein C prevents thrombin-induced thromboembolism in mice. Evidence that activated protein c reduces intravascular fibrin accumulation through the inhibition of additional thrombin generation.
Gresele P; Momi S; Berrettini M; Nenci GG; Schwarz HP; Semeraro N; Colucci M
J Clin Invest; 1998 Feb; 101(3):667-76. PubMed ID: 9449701
[TBL] [Abstract][Full Text] [Related]
31. Human renal microvascular endothelial cells as a potential target in the development of the hemolytic uremic syndrome as related to fibrinolysis factor expression, in vitro.
Louise CB; Obrig TG
Microvasc Res; 1994 May; 47(3):377-87. PubMed ID: 8084301
[TBL] [Abstract][Full Text] [Related]
32. Tumor necrosis factor-alpha and troglitazone regulate plasminogen activator inhibitor type 1 production through extracellular signal-regulated kinase- and nuclear factor-kappaB-dependent pathways in cultured human umbilical vein endothelial cells.
Hamaguchi E; Takamura T; Shimizu A; Nagai Y
J Pharmacol Exp Ther; 2003 Dec; 307(3):987-94. PubMed ID: 14534369
[TBL] [Abstract][Full Text] [Related]
33. Synthesis and in Vitro and in Vivo Anticoagulant and Antiplatelet Activities of Amidino- and Non-Amidinobenzamides.
Lee SH; Lee W; Bae JS; Ma E
Molecules; 2016 May; 21(5):. PubMed ID: 27213328
[TBL] [Abstract][Full Text] [Related]
34. Anticoagulant activities of oleanolic acid via inhibition of tissue factor expressions.
Lee W; Yang EJ; Ku SK; Song KS; Bae JS
BMB Rep; 2012 Jul; 45(7):390-5. PubMed ID: 22831973
[TBL] [Abstract][Full Text] [Related]
35. Anticoagulant and antithrombotic activity of a new peptide pENW (pGlu-Asn-Trp).
Xiong J; Fang W; Fang W; Bai L; Huo J; Kong Y; Yunman L
J Pharm Pharmacol; 2009 Jan; 61(1):89-94. PubMed ID: 19126301
[TBL] [Abstract][Full Text] [Related]
36. Changes in the fibrinolytic components of cultured human umbilical vein endothelial cells induced by endotoxin, tumor necrosis factor-alpha and interleukin-1alpha.
Orbe J; Chordá C; Montes R; Páramo JA
Haematologica; 1999 Apr; 84(4):306-11. PubMed ID: 10190943
[TBL] [Abstract][Full Text] [Related]
37. The coagulation and fibrinolytic responses of baboons after in vivo thrombin generation--effect of interleukin 6.
Kruithof EK; Mestries JC; Gascon MP; Ythier A
Thromb Haemost; 1997 May; 77(5):905-10. PubMed ID: 9184401
[TBL] [Abstract][Full Text] [Related]
38. Xanthoangelols isolated from Angelica keiskei inhibit inflammatory-induced plasminogen activator inhibitor 1 (PAI-1) production.
Ohkura N; Nakakuki Y; Taniguchi M; Kanai S; Nakayama A; Ohnishi K; Sakata T; Nohira T; Matsuda J; Baba K; Atsumi G
Biofactors; 2011; 37(6):455-61. PubMed ID: 22038782
[TBL] [Abstract][Full Text] [Related]
39. A family of arginal thrombin inhibitors related to efegatran.
Smith GF; Shuman RT; Craft TJ; Gifford DS; Kurz KD; Jones ND; Chirgadze N; Hermann RB; Coffman WJ; Sandusky GE; Roberts E; Jackson CV
Semin Thromb Hemost; 1996; 22(2):173-83. PubMed ID: 8807715
[TBL] [Abstract][Full Text] [Related]
40. Fibrinolysis in patients with acute ischaemic heart disease. With particular reference to systemic effects of tissue-type plasminogen activator treatment on fibrinolysis, coagulation and complement pathways.
Munkvad S
Dan Med Bull; 1993 Sep; 40(4):383-408. PubMed ID: 8222763
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
